#dermatology #Eli Lilly #chronic skin

Eli Lilly's Commitment to Dermatology

Eli Lilly and Company is making strides in dermatological treatment as it prepares to present its latest research data at the upcoming 2026 Fall Clinical Dermatology Conference. Scheduled for October 8-11 in Las Vegas, this event will see Lilly showcase 21 presentations centered on advanced care for chronic skin conditions, such as atopic dermatitis, psoriasis, and alopecia areata. The company aims to highlight its ongoing efforts to improve patient outcomes and address the significant challenges faced by individuals living with these chronic diseases.

Cutting-Edge Research Presentations

Among the key topics of discussion will be the innovative findings related to EBGLYSS (lebrikizumab-lbkz), demonstrating enhanced disease control and lowered dependency on topical treatments among patients with moderate-to-severe atopic dermatitis. Recent results indicate that utilizing lebrikizumab every eight weeks can provide lasting disease control, which significantly reduces flare-ups. Notably, these findings will include insights from pediatric patients as young as six months old, emphasizing the importance of safety and efficacy in younger demographics.

Adjunctive studies, such as the TOGETHER-PsO trial, will also feature prominently. This study examines the combined use of two treatments—Taltz (ixekizumab) and Zepbound (tirzepatide)—and their effects on patients who grapple with both psoriasis and obesity. The outcomes are significant as they focus on understanding the immunometabolic health of patients facing these dual struggles, offering a comprehensive view of how interconnected these conditions can be.

Addressing Everyday Burdens of Chronic Conditions

Adrienne Brown, executive vice president and president of Lilly Immunology, emphasizes the impact of chronic dermatologic diseases on day-to-day life.